

Erratum

Erratum to “Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists” [Bioorg. Med. Chem. Lett. 16 (2006) 4652–4656]

Dann L. Parker, Jr.,^{a,*} Dongfang Meng,^a Ronald W. Ratcliffe,^a Robert R. Wilkening,^a
Donald M. Sperbeck,^a Mark L. Greenlee,^a Lawrence F. Colwell,^a Sherrie Lambert,^a
Elizabeth T. Birzin,^b Katalin Frisch,^b Susan P. Rohrer,^b Stefan Nilsson,^c
Ann-Gerd Thorsell^c and Milton L. Hammond^a

^aDepartment of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA

^bDepartment of Atherosclerosis and Endocrinology, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA

^cKaroBio AB, Novum, S-14157 Huddinge, Sweden

The publisher regrets that the structures in [Figure 1](#) are labeled incorrectly. The corrected figure appears here.




Figure 1. ER β ligands based on tetrahydrofluorenones.

DOI of original article: [10.1016/j.bmcl.2006.05.103](https://doi.org/10.1016/j.bmcl.2006.05.103).

* Corresponding author. Tel.: +1 732 594 4586; fax: +1 732 594 9556; e-mail: dann_parker@merck.com